ライフサイエンスコーパス: pegaptanib

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 lly significant (P < 0.05) benefits favoring pegaptanib.

2 At 2 years, the VA trend favored pegaptanib.

3 izumab and 200-fold more potent than that of pegaptanib.

4 ed safety risk resulting from treatment with pegaptanib 0.3 mg in individuals with neovascular age-re

5 More patients receiving pegaptanib (0.3 mg), as compared with sham injection, ma

6 9), followed by ranibizumab (44.1%, n = 41), pegaptanib (7.5%, n = 7), and aflibercept (5.4%, n = 5).

7 Pegaptanib, an anti-vascular endothelial growth factor t

8 (bevacizumab, ranibizumab, aflibercept, and pegaptanib) and intraocular steroids (triamcinolone and

9 One hundred thirty-three pegaptanib- and 127 sham-treated subjects were in the ye

10 k 54, >/= 10 letter gains seen in 49 (36.8%) pegaptanib- and 25 (19.7%) sham-treated subjects (odds r

11 Pegaptanib appears to be an effective therapy for neovas

12 In the group given pegaptanib at 0.3 mg, 70 percent of patients lost fewer

13 treous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or s

14 Subjects who received pegaptanib by randomization or change in dose assignment

15 Unlike bevacizumab, pegaptanib did not interact directly with VEGF-A(165)b.

16 Studies for bevacizumab, aflibercept, and pegaptanib in DME were limited but also in favor of anti

17 ith the terms "bevacizumab OR ranibizumab OR pegaptanib OR aflibercept" and the limitations "humans"

18 amer therapeutic approved for use in humans (Pegaptanib or Macugen).

19 In year 1, pegaptanib or sham was administered every 6 weeks with f

20 esponse relationship, for all three doses of pegaptanib (P<0.001 for the comparison of 0.3 mg with sh

21 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001).

22 Intravitreal pegaptanib sodium (0.3 mg) improved vision and reduced c

23 To evaluate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the t

24 icantly greater effect of the combination of pegaptanib sodium and PDT on lesion size in choroidal ne

25 The combination of pegaptanib sodium and PDT resulted in the regression of

26 Two anti-VEGF agents, pegaptanib sodium and ranibizumab, are currently approve

27 Pretreatment with pegaptanib sodium appeared to decrease the efficacy of P

28 t provides level I evidence for intravitreal pegaptanib sodium for DME.

29 ion of pegaptanib sodium nor the efficacy of pegaptanib sodium in the inhibition of VEGF165 binding t

30 nt of ocular neovascularization with PDT and pegaptanib sodium may provide a more effective approach

31 In contrast, pegaptanib sodium monotherapy yielded little regression

32 T did not affect the chemical composition of pegaptanib sodium nor the efficacy of pegaptanib sodium

33 herapy's (PDT's) effects on the integrity of pegaptanib sodium were analyzed by HPLC, a VEGF165-bindi

34 evacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were reviewed for 2465 patients betwe

35 Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap,

36 al acuity among patients receiving 0.3 mg of pegaptanib was better than in those receiving sham injec

37 trial first showed that an anti-VEGF agent (pegaptanib) was able to prevent vision loss in neovascul

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。